ZYME Insider Trading
Insider Ownership Percentage: 1.92%
Insider Buying (Last 12 Months): $23,696,890.81
Insider Selling (Last 12 Months): $1,336,846.92
Zymeworks Insider Trading History Chart
This chart shows the insider buying and selling history at Zymeworks by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Zymeworks Share Price & Price History
Current Price: $11.53
Price Change: ▲ Price Increase of +0.28 (2.49%)
As of 04/17/2025 05:00 PM ET
Zymeworks Insider Trading History
Zymeworks Institutional Trading History
Data available starting January 2016
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Read More on Zymeworks
Today's Range
Now: $11.53
52 Week Range
Now: $11.53
Volume
383,335 shs
Average Volume
621,012 shs
Market Capitalization
$802.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
Who are the company insiders with the largest holdings of Zymeworks?
Who are the major institutional investors of Zymeworks?
Zymeworks' top institutional investors include:
- Assenagon Asset Management S.A. — 0.71%
- SG Americas Securities LLC — 0.14%
- Rhumbline Advisers — 0.12%
- Ritholtz Wealth Management — 0.09%
- Janney Montgomery Scott LLC — 0.02%
- Exchange Traded Concepts LLC — 0.01%
Learn More about top institutional investors of Zymeworks stock.
Which major investors are selling Zymeworks stock?
During the last quarter, ZYME stock was sold by these institutional investors:
- Assenagon Asset Management S.A.
- Rhumbline Advisers
- Ritholtz Wealth Management
- Exchange Traded Concepts LLC
During the previous year, company insiders that have sold Zymeworks company stock include:
- Ecor1 Capital, Llc (Director)
- Ecor1 Capital, Llc (Major Shareholder)
- Kenneth Galbraith (CEO)
Learn More investors selling Zymeworks stock.
Which major investors are buying Zymeworks stock?
Within the previous quarter, ZYME stock was purchased by institutional investors including:
- SG Americas Securities LLC
- GAMMA Investing LLC
- Janney Montgomery Scott LLC
During the last year, these company insiders have bought Zymeworks stock:
- Ecor1 Capital, Llc (Director)
- Ecor1 Capital, Llc (Major Shareholder)
Learn More investors buying Zymeworks stock.